Trial Profile
A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination With Nivolumab in Subjects With Selected Advanced Solid Tumors or Hematologic Malignancies
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Jun 2022
Price :
$35
*
At a glance
- Drugs BMS 986158 (Primary) ; Nivolumab (Primary)
- Indications Advanced breast cancer; Fallopian tube cancer; Haematological malignancies; Ovarian cancer; Peritoneal cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Bristol-Myers Squibb
- 08 Feb 2022 Status changed from active, no longer recruiting to completed.
- 31 Jul 2021 This trial is discontinued in Belgium (End Date: 22 Dec 2020), according to European Clinical Trials Database record.
- 09 Apr 2021 This trial is discontinued in Spain (Global End Date: 22 Dec 2020), according to European Clinical Trials Database record.